Lead Product(s) : Adrabetadex
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : INPDR
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The partnership will provide Mandos Health with real-world evidence that will directly inform the development of its Niemann-Pick type C1 (NPC1) investigational product, VTS-270 (adrabetadex).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 16, 2023
Lead Product(s) : Adrabetadex
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : INPDR
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Adrabetadex
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
Details : Adrabetadex is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Niemann-Pick Disease, Type C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Adrabetadex
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adrabetadex
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System
Details : Adrabetadex is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Niemann-Pick Disease, Type C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 23, 2018
Lead Product(s) : Adrabetadex
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adrabetadex
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
Details : Adrabetadex is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Niemann-Pick Disease, Type C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2015
Lead Product(s) : Adrabetadex
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable